Informações de Biogen Inc | Histórico, dados financeiros e desempenho de mercado

Mais detalhes de Biogen Inc Empresa

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Informações da empresa

Código da empresaBIIB

Nome da EmpresaBiogen Inc

Data de listagemSep 17, 1991

Fundado em1997

CEOMr. Christopher A. (Chris) Viehbacher

Número de funcionários7605

Tipo de títulosOrdinary Share

Fim do ano fiscalSep 17

Endereço225 Binney Street

CidadeCAMBRIDGE

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal02142

Telefone17814642000

Sitehttps://www.biogen.com/

Código da empresaBIIB

Data de listagemSep 17, 1991

Fundado em1997

Executivos da empresa

Nome

Nome/Posição

Posição

Ações detidas

Variação

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

36.27K

+14.76%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

25.03K

+7.68%

Dr. Ginger Gregory, Ph.D.

Chief Human Resource Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.06K

+45.88%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

13.45K

+38.65%

Dr. Stephen A. Sherwin, M.D.

Independent Director

10.36K

-45.82%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

8.88K

+36.82%

Mr. Jesus B. Mantas

Independent Director

6.43K

+26.34%

Dr. Maria C. Freire, Ph.D.

Independent Director

3.48K

+62.47%

Dr. Adam James Keeney, Ph.D.

Executive Vice President, Head of Corporate Development

1.90K

+187.01%

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

36.27K

+14.76%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

25.03K

+7.68%

Dr. Ginger Gregory, Ph.D.

Chief Human Resource Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.06K

+45.88%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

13.45K

+38.65%

Dr. Stephen A. Sherwin, M.D.

Independent Director

10.36K

-45.82%

Detalhamento da receita

Moeda: USDTempo de atualização: dom, 6 de abr

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Spinal Muscular Atrophy-SPINRAZA

1.99B

20.55%

MS product revenues-TYSABRI

1.72B

17.72%

MS product revenues-Fumarate

1.60B

16.49%

MS product revenues-Interferon

968.00M

10.00%

Biosimilar product revenues-BENEPALI

479.10M

4.95%

Other

2.93B

30.29%

Por RegiãoUSD

Nome

Receita

Proporção

Rest of World

3.98B

41.09%

United States

3.30B

34.08%

United states-Revenues from anti-CD20 therapeutic

1.75B

18.09%

Rest of World-Other revenues

652.60M

6.74%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Spinal Muscular Atrophy-SPINRAZA

1.99B

20.55%

MS product revenues-TYSABRI

1.72B

17.72%

MS product revenues-Fumarate

1.60B

16.49%

MS product revenues-Interferon

968.00M

10.00%

Biosimilar product revenues-BENEPALI

479.10M

4.95%

Other

2.93B

30.29%

Acionista

Tempo de atualização: sex, 21 de fev

Estatísticas dos acionistas

Tipo

Estatísticas dos acionistas

Acionista

Proporção

The Vanguard Group, Inc.

11.39%

PRIMECAP Management Company

10.96%

BlackRock Institutional Trust Company, N.A.

5.87%

State Street Global Advisors (US)

5.05%

Wellington Management Company, LLP

3.37%

Other

63.35%

Estatísticas dos acionistas

Acionista

Proporção

The Vanguard Group, Inc.

11.39%

PRIMECAP Management Company

10.96%

BlackRock Institutional Trust Company, N.A.

5.87%

State Street Global Advisors (US)

5.05%

Wellington Management Company, LLP

3.37%

Other

63.35%

Tipo

Acionista

Proporção

Investment Advisor

43.69%

Investment Advisor/Hedge Fund

36.85%

Hedge Fund

5.46%

Research Firm

2.82%

Pension Fund

2.29%

Bank and Trust

1.74%

Sovereign Wealth Fund

1.67%

Private Equity

0.35%

Individual Investor

0.15%

Other

4.99%

Participação acionária institucional

Tempo de atualização: seg, 20 de jan

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q1

2074

138.81M

94.83%

-5.05M

2024Q4

2130

138.58M

94.69%

-5.19M

2024Q3

2109

135.95M

93.33%

-6.54M

2024Q2

2116

135.72M

93.21%

-7.14M

2024Q1

2121

136.44M

93.87%

-5.95M

2023Q4

2151

135.61M

93.59%

-2.07M

2023Q3

2177

132.42M

91.43%

-7.53M

2023Q2

2240

133.77M

92.42%

-4.86M

2023Q1

2280

132.71M

91.84%

-5.88M

2022Q4

2292

132.00M

91.64%

-4.78M

Ver Mais

Atividade dos acionistas

Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

16.68M

11.39%

+1.13K

+0.01%

Dec 31, 2024

PRIMECAP Management Company

16.05M

10.96%

-268.87K

-1.65%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

8.59M

5.87%

+23.69K

+0.28%

Dec 31, 2024

State Street Global Advisors (US)

7.40M

5.05%

+53.29K

+0.73%

Dec 31, 2024

Wellington Management Company, LLP

4.93M

3.37%

-200.47K

-3.91%

Dec 31, 2024

Geode Capital Management, L.L.C.

3.70M

2.52%

+82.46K

+2.28%

Dec 31, 2024

T. Rowe Price Investment Management, Inc.

3.10M

2.12%

-1.16M

-27.17%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

3.01M

2.06%

+40.53K

+1.36%

Feb 28, 2025

Pacer Advisors, Inc.

2.67M

1.82%

+2.65M

+13.57K%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

2.33M

1.59%

+246.45K

+11.86%

Dec 31, 2024

Ver Mais

ETFs Relacionados

Tempo de atualização: dom, 6 de abr

Nome

Proporção

Invesco Biotechnology & Genome ETF

4.41%

iShares Neuroscience and Healthcare ETF

3.82%

Global X US Cash Flow Kings 100 ETF

3.55%

VanEck Biotech ETF

3.23%

Tema Neuroscience and Mental Health ETF

3.15%

Alger Russell Innovation ETF

3.04%

First Trust NYSE Arca Biotechnology Index Fund

2.94%

First Trust NASDAQ Pharmaceuticals ETF

2.89%

Invesco Pharmaceuticals ETF

2.39%

SPDR S&P Biotech ETF

2.19%

Ver Mais

Invesco Biotechnology & Genome ETF

Proporção4.41%

iShares Neuroscience and Healthcare ETF

Proporção3.82%

Global X US Cash Flow Kings 100 ETF

Proporção3.55%

VanEck Biotech ETF

Proporção3.23%

Tema Neuroscience and Mental Health ETF

Proporção3.15%

Alger Russell Innovation ETF

Proporção3.04%

First Trust NYSE Arca Biotechnology Index Fund

Proporção2.94%

First Trust NASDAQ Pharmaceuticals ETF

Proporção2.89%

Invesco Pharmaceuticals ETF

Proporção2.39%

SPDR S&P Biotech ETF

Proporção2.19%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações

Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados

Biogen Inc

118.840USD

Biogen Inc

118.840

Visão Geral

Empresa